Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Patients

被引：5
|
作者：
Thomas, Melissa K.
Nikooienejad, Amir
Bray, Ross
Cui, Xuewei
Wilson, Jonathan M.
Duffin, Kevin L.
Milicevic, Zvonko
Haupt, Axel
Robins, Deborah A.
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-980-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
980-P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
    Ma, Zijun
    Jin, Kaiqin
    Yue, Mengmeng
    Chen, Xin
    Chen, Jun
    JOURNAL OF DIABETES RESEARCH, 2023, 2023
  • [42] Role of Dual GIP and GLP-1 Receptor Agonist, Tirzepatide in the Management of Weight Loss; A Systematic Review
    Rangraze, Imran Rashid
    Khan, Shehla
    Wali, Adil Farooq
    Menezes, Godfred
    Goud, Manjunatha
    Jabran, Muhammad
    CURRENT DRUG SAFETY, 2024,
  • [43] The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
    Frias, Juan Pablo
    Bastyr, Edward J., III
    Vignati, Louis
    Tschoep, Matthias H.
    Schmitt, Christophe
    Owen, Klara
    Christensen, Rune Haubo
    DiMarchi, Richard D.
    CELL METABOLISM, 2017, 26 (02) : 343 - +
  • [44] The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist
    Urva, Shweta
    Nauck, Michael A.
    Coskun, Tamer
    Cui, Xuewei
    Haupt, Axel
    Benson, Charles
    Loghin, Corina
    DIABETES, 2019, 68
  • [45] The novel dual GIP and GLP-1 receptor agonist, tirzepatide, transiently delays gastric emptying similarly to a selective long-acting GLP-1 receptor agonist
    Urva, S.
    Nauck, M. A.
    Coskun, T.
    Cui, X.
    Haupt, A.
    Benson, C. T.
    Loghin, C.
    DIABETOLOGIA, 2019, 62 : S58 - S58
  • [46] Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis
    Stefanou, Maria-Ioanna
    Theodorou, Aikaterini
    Malhotra, Konark
    Aguiar de Sousa, Diana
    Katan, Mira
    Palaiodimou, Lina
    Katsanos, Aristeidis H.
    Koutroulou, Ioanna
    Lambadiari, Vaia
    Lemmens, Robin
    Giannopoulos, Sotirios
    Alexandrov, Andrei, V
    Siasos, Gerasimos
    Tsivgoulis, Georgios
    EUROPEAN STROKE JOURNAL, 2024, 9 (03) : 530 - 539
  • [47] Efficacy and safety of once weekly tirzepatide, a dual GIP/GLP-1 receptor agonist versus placebo as monotherapy in people with type 2 diabetes (SURPASS-1)
    Rosenstock, J.
    Wysham, C.
    Frias, J. P.
    Kaneko, S.
    Lee, C. J.
    Lando, L. Fernandez
    Mao, H.
    Cui, X.
    Thieu, V. T.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 246 - 246
  • [48] Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
    Pirro, Valentina
    Roth, Kenneth D.
    Lin, Yanzhu
    Willency, Jill A.
    Milligan, Paul L.
    Wilson, Jonathan M.
    Ruotolo, Giacomo
    Haupt, Axel
    Newgard, Christopher B.
    Duffin, Kevin L.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (02): : 363 - 378
  • [49] Tirzepatide: NICE recommends another GLP-1 agonist for type 2 diabetes
    Mahase, Elisabeth
    BMJ-BRITISH MEDICAL JOURNAL, 2023, 382 : 2074
  • [50] Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
    Michael A. Nauck
    David A. D‘Alessio
    Cardiovascular Diabetology, 21
12345